https://charts.traderzeitung.de/phases/US8684591089
string(1462) "{"isin":"US8684591089","name":"Supernus Pharmaceuticals Inc","stock_id_xnas":7875055,"stock_id_xnys":null,"generated_at":"2026-08-31 11:20:00","days":[{"date":"2026-08-26","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":45,"close_at":"2026-08-26 15:28:00","complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":44.89,"close_at":"2026-08-26 21:59:00","complete":true,"perf_pct":-0.2444},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-08-27","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":44.75,"close_at":"2026-08-27 15:28:00","complete":true,"perf_pct":-0.3119},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":44.21,"close_at":"2026-08-27 21:59:00","complete":true,"perf_pct":-1.2067},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-08-28","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":44,"close_at":"2026-08-28 15:29:00","complete":true,"perf_pct":-0.475},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":43.76,"close_at":"2026-08-28 21:59:00","complete":true,"perf_pct":-0.5455},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]}]}"
Supernus Pharmaceuticals Aktie News & Nachrichten
Trading-Room

Supernus Pharmaceuticals Aktie News & Nachrichten

[WKN: A1JX3U | Symbol: SUPN]
Realtimekurs
   
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005, and is headquartered in Rockville, MD.
Vorbörsliche Indikationen
Regulärer Handel
Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Supernus Pharmaceuticals

Pivotal-Point Nachverfolgung Supernus Pharmaceuticals (SUPN): Kursziel-Explosion nach Piper Sandler-Upgrade – Parkinson-Medikament Onapgo als neuer Umsatz-Star!

Supernus Pharmaceuticals ist ein auf die Biopharmazie spezialisiertes Unternehmen, das sich auf die Entwicklung...

Pivotal-Point Nachverfolgung Supernus Pharmaceuticals (SUPN): Kursziel-Explosion nach Piper Sandler-Upgrade – Parkinson-Medikament Onapgo als neuer Umsatz-Star!

Supernus Pharmaceuticals ist ein biopharmazeutisches Unternehmen aus den USA, das sich auf die Entwicklung...

TOP-5-Kursziele der Analysten am 09.10.25

HelloFresh [DE000A161408] UBS nimmt Hochstufung von "Neutral" auf "Buy" vor und erhöht das Kursziel...

  • ‹
  • 1
  • ›
Supernus Pharmaceuticals Nachrichtenticker öffnen
MT Newswires 03.08.2026 15:16 Uhr

Sektor-Update: Gesundheitsaktien steigen am Montagmorgen vorbörslich

09:15 AM EDT, 08/03/2026 (MT Newswires) -- Gesundheitsaktien sind am Montagmorgen vorbörslich gestiegen, wobei der State Street Health Care Select Sec

MT Newswires 03.08.2026 13:16 Uhr

Supernus Pharmaceuticals und Indivior Pharmaceuticals fusionieren im Rahmen einer reine Aktientransaktion

07:15 AM EDT, 03.08.2026 (MT Newswires) -- Supernus Pharmaceuticals (SUPN) und Indivior Pharmaceuticals (INDV) teilten am Montag mit, dass sie in eine

MT Newswires 03.08.2026 13:12 Uhr

Supernus Pharmaceuticals verzeichnet im Q2 Nettoverlust, Umsatz steigt; Umsatzprognose für das Geschäftsjahr 2026 angehoben

07:11 AM EDT, 08/03/2026 (MT Newswires) -- Supernus Pharmaceuticals, Inc. (SUPN) meldete am Montag einen Nettoverlust im Q2 von 1,01 USD je Aktie, wom

MT Newswires 03.08.2026 12:53 Uhr

Indivior Pharmaceuticals, Supernus Pharmaceuticals to Combine in All-Stock Merger

06:52 AM EDT, 08/03/2026 (MT Newswires) -- http://www.mtnewswires.com Copyright © 2026 MT Newswires. All rights reserved. MT Newswires does not provid

MT Newswires 03.08.2026 12:39 Uhr

--Earnings Flash (SUPN) Supernus Pharmaceuticals verzeichnet Nettoverlust im Q2 von 1,01 USD je Aktie, verglichen mit FactSet-Schätzung von 0,04 USD EPS

06:38 AM EDT, 03.08.2026 (MT Newswires) -- http://www.mtnewswires.com Copyright © 2026 MT Newswires. All rights reserved. MT Newswires does not provid

MT Newswires 03.08.2026 12:38 Uhr

-- Earnings Flash (SUPN) Supernus Pharmaceuticals, Inc. Meldet Q2 Umsatz von 219,1 Mio. USD, verglichen mit FactSet-Schätzung von 205,3 Mio. USD

06:36 AM EDT, 08/03/2026 (MT Newswires) -- http://www.mtnewswires.com Copyright © 2026 MT Newswires. All rights reserved. MT Newswires does not provid